Page 86 - ARNM-2-4

Advances in Radiotherapy
& Nuclear Medicine Dose-volume histogram and gamma analysis

verified in the displacements related to the longitudinal 304921/2021-1); São Paulo Research Foundation (FAPESP)
axis in relation to the bladders’ DVH. (Grants 2021/02254-6, and CEPID-NEUROMAT
This finding of Figure 6 is justified by the dimensions 2013/07699-0), and Sistema Único de Saúde (SUS).
of the volumes of the delimited structures and their spatial Conflict of interest
location in relation to the treatment target.
The authors declare that they have no competing interests.
The treatment volume, as defined, presents its
anteroposterior dimension considerably smaller than the Author contributions
others, being 35% smaller than the lateral dimension and
60% smaller than the craniocaudal dimension. Critical Conceptualization: All authors
structures also present significant differences in their Investigation: Larisse Neumann Bonatto
volumes, and again, the anteroposterior dimension is the Methodology: All authors
smallest of all, as described above. In addition, anatomically, Writing – original draft: Larisse Neumann Bonatto
the prostate is situated posterior to the bladder and anterior Writing – review & editing: Alexandre Colello Bruno,
to the rectum, precisely on the axis where all the involved Oswaldo Baffa, Juliana Fernandes Pavoni
structures present their smallest dimensions. Therefore, Ethics approval and consent to participate
even the smallest variation in this axis will cause greater
variation in irradiated volumes in relation to the other two This work reposts a simulation study of a clinical problem;
axes in which the structures present larger dimensions it doesn’t include humans, so it is not necessary to have the
than those in less critical anatomical locations. local ethics committee’s approval.
The limitation of this study is that all the data are based Consent for publication
on the simulated prostate cancer treatment plan using the
solid water phantom created based on the TG-119 protocol No patients or volunteers were involved.
of AAPM. Although this study yielded some insights Availability of data
12
related to the percentage of points approved in the 3DGI
analysis and DVH doses for various displacements, a larger Data are available from the corresponding author upon
study including human patients with anatomic variations reasonable request.
would be necessary to validate the findings of the present
study in real-world settings. References
1. Cancer Today. Available from: https://gco.iarc.who.int/
5. Conclusion today [Last accessed on 2024 Jun 20].
This study demonstrated that the percentage of points 2. Howlader N, Noone A, Krapcho M, et al. SEER Cancer
approved in the 3DGI analysis was linearly related to Statistics Review, 1975-2018. National Cancer Institute; 2021.
the PTV dose. Similar behavior was also observed in the Available from: https://seer.cancer.gov/csr/1975_2018/
DVHs for the bladder and rectum, but the relationship index.html [Last accessed on 2024 Jun 20]
was not the same for these structures in lateral, vertical, 3. Schaeffer EM, Srinivas S, Adra N, et al. Prostate cancer,
and longitudinal displaced axes. Nevertheless, more robust version 4. NCCN clinical practice guidelines in oncology.
research is warranted to assess whether such behavior J Natl Compr Canc Netw. 2023;21(10):1067-1096.
will reproduce in a greater number of cases and plan with doi: 10.6004/jnccn.2023.0050
varying levels of complexity. We propose a future study
to verify if 3DGI analysis can provide relevant clinical 4. Tilki D, Van den Bergh RCN, Briers E, et al. EAU-EANM-
information and complementary evaluation useful for ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer.
Part II-2024 update: Treatment of relapsing and metastatic
informing the approval or rejection of a treatment plan.
prostate cancer. Eur Urol. 2024;86:164-182.
Acknowledgments doi: 10.1016/j.eururo.2024.04.010
The authors Carlos Renato Silva and Lourenço Rocha for 5. Cornford P, Van den Bergh RC, Briers E, et al. EAU-
the technical assistance. EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate
cancer-2024 Update. Part I: Screening, diagnosis, and local
Funding treatment with curative Intentt. Eur Urol. 2024;86(2):148-163.

This work was financially supported by the Brazilian doi: 10.1016/j.eururo.2024.03.027
Agencies: CNPq (Grants 407471/2016-, 305827/2023-5 and 6. Miften M, Olch A, Mihailidis D, et al. Tolerance limits and

Volume 2 Issue 4 (2024) 6 doi: 10.36922/arnm.4005